This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emisphere Technologies, Inc.
Drug Names(s): oral heparin
Description: Oral heparin is a formulation of the anticoagulant heparin, which currently must be injected, using Emisphere'sproprietary compound Sodium N-[8(-2-hydroxybenzoy l) amino] caprylate (SNAC), a delivery agent that can be combined with heparin to mediate itsgastrointestinal absorption by a passive transcellular process, withoutapparent damage to intestinal epithelium. The formulation under development is a solid form of oral heparin.
Deal Structure: In 1996, the Emisphere formed a joint venture with Elan Pharmaceuticalsfor the development of an oral heparin. In July 1999, however, they reacquired allproduct, marketing and technology rights for these heparin product candidatesfrom Elan.
Additional information available to subscribers only: